These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Manyam BV; Dhanasekaran M; Hare TA Phytother Res; 2004 Sep; 18(9):706-12. PubMed ID: 15478206 [TBL] [Abstract][Full Text] [Related]
10. Acorus gramineus inhibits microglia mediated neuroinflammation and prevents neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease. Jiang J; Kim JJ; Kim DY; Kim MK; Oh NH; Koppula S; Park PJ; Choi DK; Shin YK; Kim IH; Kang TB; Lee KH J Ethnopharmacol; 2012 Dec; 144(3):506-13. PubMed ID: 23085397 [TBL] [Abstract][Full Text] [Related]
11. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573 [TBL] [Abstract][Full Text] [Related]
12. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. Cassani E; Cilia R; Laguna J; Barichella M; Contin M; Cereda E; Isaias IU; Sparvoli F; Akpalu A; Budu KO; Scarpa MT; Pezzoli G J Neurol Sci; 2016 Jun; 365():175-80. PubMed ID: 27206902 [TBL] [Abstract][Full Text] [Related]
14. Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models. Wang Q; Qian L; Chen SH; Chu CH; Wilson B; Oyarzabal E; Ali S; Robinson B; Rao D; Hong JS Brain; 2015 May; 138(Pt 5):1247-62. PubMed ID: 25716193 [TBL] [Abstract][Full Text] [Related]
15. [Survey on the Current Advertising and Sales of Mucuna pruriens in Consumer-to-consumer Internet Trading in Japan]. Sato K; Hida A; Niimi Y; Iwata A; Iwatsubo T Yakugaku Zasshi; 2023 Dec; 143(12):1057-1067. PubMed ID: 37839871 [TBL] [Abstract][Full Text] [Related]
16. Mucuna pruriens to treat Parkinson's disease in low-income countries: Recommendations and practical guidelines from the farmer to clinical trials. Paving the way for future use in clinical practice. Caronni S; Del Sorbo F; Barichella M; Fothergill-Misbah N; Denne T; Laguna J; Urasa S; Dekker MCJ; Akpalu A; Sarfo FS; Cham M; Pezzoli G; Cilia R Parkinsonism Relat Disord; 2024 Jul; 124():106983. PubMed ID: 38797572 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Olson KE; Gendelman HE Curr Opin Pharmacol; 2016 Feb; 26():87-95. PubMed ID: 26571205 [TBL] [Abstract][Full Text] [Related]
18. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model. Zahra W; Rai SN; Birla H; Singh SS; Rathore AS; Dilnashin H; Singh R; Keswani C; Singh RK; Singh SP CNS Neurol Disord Drug Targets; 2020; 19(7):527-540. PubMed ID: 32787765 [TBL] [Abstract][Full Text] [Related]
20. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. Katzenschlager R; Evans A; Manson A; Patsalos PN; Ratnaraj N; Watt H; Timmermann L; Van der Giessen R; Lees AJ J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1672-7. PubMed ID: 15548480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]